Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | PDE6D | O43924 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084409 | 1.00 | HMGCR (0.68) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1164445 | 1.00 | HMGCR (0.68) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3084408 | 1.00 | HMGCR (0.68) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL18269420 | 0.94 | HMGCR (0.66) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL18260132 | 0.94 | HMGCR (0.66) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL18260135 | 0.94 | HMGCR (0.66) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL17877789 | 0.91 | HMGCR (0.69) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4600766 | 0.90 | HMGCR (0.67) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4159337 | 0.89 | HMGCR (0.78) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4209321 | 0.89 | HMGCR (0.78) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846915-B2 | Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester | AUROBINDO PHARMA LTD. (IN) | 2014-09-30 | — | — | US | disclosed |
| US-20120149905-A1 | PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM USING CRYSTALLINE ROSUVASTATIN ETHYL ESTER | AUROBINDO PHARMA LTD (IN) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149905-A1 | PROCESS FOR THE MANUFACTURE OF ROSUVASTATIN CALCIUM USING CRYSTALLINE ROSUVASTATIN ETHYL ESTER | HMGCR, CYP4A11, PCSK9 | HMGCR 1/4885ALDH1A1 3076/4885CYP3A4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.